Cancer Centers of America opened its first hospital in 1988. The founder, Richard J Stephenson created the center as a labor of love. His mother died of cancer and what he deemed to be an unsatisfactory treatment plan. This was a way to combine the best cancer physicians and an integrative cancer treatment plan that approaches the patient as an individual. Along with traditional methods of treatment, also included are treatments for the many side effects of radiation.
A Merger Creates A Stronger Center
Cancer Centers Of America has merged with Allscripts and Nanthealth to now enable eviti, a clinical decision support system to access the clinical workflows while leaving the workflow undisturbed.
Hundreds of Oncologists across the nation are members. This means that physicians have access to a full database of Oncology treatments and cancer care data. Because it offers all appropriate treatment options, it will eliminate guesswork. Clinicians are bombarded with data routinely and this will help make the way clearer resulting in even higher quality care.
Designed With The Patient In Mind
The latest cancer research, along with the complementary therapies are entered into Allscripts Sunrise EHR. This gives Oncologists all available treatment options in one space.
The System Provides
A care plan that is a tailored to the patient; the disease stage; the personal state of health.
Comparative list of options with cost of delivery
Tap screen ordering system
Each treatment offering comes complete with the integrative approach. This includes the evidence based treatment and complementary options for support.
Both the Oncologist and the patient will have access to up-to-date treatment results; success rates and toxicity.
This system provides all relevant data to the patient. This means a more supported treatment where educated, clear decisions can be made.
To Learn More : www.opensecrets.org/orgs/summary.php?id=D000032265
Yafang Li, PhD. led a Dartmouth research team in a study on the role gene-smoking interactions play in the etiology of lung cancer. The study which was published in Carcinogenesis identified three new lung cancer genetic biomarkers. The study revealed three SNP’s(single nucleotide polymorphisms) in DNA that form the foundation of our susceptibility to developing cancer. Two of the SNP’s were for the risk of non-small cell lung cancer, and the other was for the risk of squamous cell lung cancer.
These three SNP’s the study identified provided potential candidate biomarkers for lung cancer risk screening and intervention. The team’s findings were limited to the smoking behavior and non-small cell lung cancer risk in the Caucasian population. Because of this restriction, the results are not applicable to other ethnicities, but suggest a breakthrough in the treatment of lung cancer is on the horizon.
The breakthrough that these results make in cancer research is good news for all who long for a cure. Eric Lefkofsky like so many others believes that a cure for cancer can be found if the way we diagnose and treat the disease change. Lefkofsky has donated millions of dollars towards cancer research. In 2006 he and his wife established the Lefkofsky Family Foundation. This foundation is a private charitable foundation that uses high-impact initiatives to enhance the lives close to their community in Chicago. The foundation provides funding for education, healthcare, medical research, and arts and culture.
Mr. Lefkofsky is an American entrepreneur who wears many hats. A graduate of the University of Michigan, he is an adjunct professor at the University of Chicago; he is the co-founder and CEO of TEMPUS; the co-founder of Echo Global Logistics; and he is involved on a corporate level with Inner Workings, Mediacean, and Uptake.. It is his work with Tempus, however, that will benefit most from the findings of Dr. Li’s study.
Tempus is a health tech company that’s “building the infrastructure to modernize cancer treatment.” Tempus collects and analyzes genomic data to uncover ways that will enable physicians to provide more precise and personalized treatments for their patients. The data driven treatment decisions used by Tempus analyzes “a patient’s genetic code in the context of molecular therapies” seems a good fit for the Dartmouth’s study groups findings.
Tempus believes that their efforts will propel the next advancement in healthcare. We all stand on the shoulders of men like Lefkofsky as we wait for it.
Visit More Click Here
Eric Lefkofsky is the founder and the CEO of Tempus. Tempus is a technology company responsible for building an operating system to help in the fight against cancer. The technology provided by Tempus helps doctors to deliver personalized care for cancer patients. Through analyzing molecular and clinical data, Tempus enables physicians to make a rational data-based decision. Eric Lefkofsky is also a co-founder and managing director of Lightbank, a business enterprise that invests in disruptive technologies. Eric Lefkofsky is also a co-founder and a chairman of Groupon, a global e-commerce marketplace. He is also a co-founder of Uptake Technologies, Mediaocean, Echo Global Logistics, and Innerworks.
Eric Lefkofsky founded a private charitable foundation known as the Lefkofsky Family Foundation. This was in a bid to come up with high-end initiatives to enhance lives in the communities he served. Eric is a man who has endeavored to better his community in great ways. The American entrepreneur was born on September 2, 1969. He grew up in Southfield, Michigan and attended his university studies at the University of Michigan where he graduated with honors in 1991. Eric Lefkofsky continued his education at the University of Michigan Law School where he received his Juris Doctor in 1993. He also attained a degree in Bachelor of Art/Science at the University of Michigan to learn more: http://lefkofskyfoundation.com/ click here.
Eric Lefkofsky is one of the most influential tech figures in Chicago. This philanthropic entrepreneur and author have donated millions of dollars to facilitate cancer research. Eric is now using Tempus as a smarter approach to finding cancer treatment. The American businessman who is also a billionaire has so much towards realizing a better world. With his passion for technology, he has continued to come up with ventures that have impacted lives quite remarkably.
Lefkofsky and his wife Liz have continued to donate massive amounts of money especially in the fight against cancer. Among his philanthropic deeds, Lefkofsky gave $1 million dollars to Robert H. Lurie Comprehensive Cancer Center of Northwestern, $500,000 in support of immunotherapy for gastric cancer, $1.2 million to the University of Michigan to aid cancer research and many others. As a matter of facts, Eric Lefkofsky became a member of The Giving Pledge. He promised to donate at least half of his wealth to philanthropy through his life.
Eric Lefkofsky is also an adjunct professor at the University of Chicago and has authored the book ‘Accelerated Disruption. Eric Lefkofsky has proved to be quite successful in basically everything he ventures. This is an attribute which has made him among top American serial entrepreneurs.
Lefkofsky is dedicated and focused; this has seen him rise to high levels in his life. He has also given back to his community in remarkable portions. He has donated liquid cash primarily to aid fight against cancer. This outstanding entrepreneur has also dedicated his life to finding the cure for cancer through the Tempus Company. With the unique technology of sequencing and analytics being provided by the Tempus Company, Eric Lefkofsky is a man who has made quite a mark on the lives of millions.